期刊文献+

TIMP-4在膀胱癌及癌旁正常膀胱组织中的表达 被引量:4

Expression of mammalian tissue inhibitor of metalloproteinase-4 in bladder carcinoma and normal tissue adjacent to carcinoma
下载PDF
导出
摘要 目的探讨基质金属蛋白酶抑制剂-4(TIMP-4)在膀胱癌组织与癌旁组织中的表达及其临床意义。方法收集2015年6月~2016年9月西京医院泌尿外科152例膀胱尿路上皮癌患者手术标本的癌组织及其癌旁组织,利用免疫组织化学染色法分别对其进行染色,并在显微镜下观察组织切片染色情况,运用半定量法分析膀胱癌组织及癌旁组织中TIMP-4蛋白的表达情况。结果 TIMP-4蛋白免疫反应物主要沉积于细胞质。膀胱癌组织与癌旁组织中TIMP-4蛋白染色阳性率分别为26.97%和84.21%,差异有统计学意义(P<0.05)。低级别膀胱乳头状尿路上皮癌与高级别膀胱乳头状尿路上皮癌组织中TIMP-4蛋白染色阳性率分别为38.71%和18.89%,差异有统计学意义(P<0.05)。结论 TIMP-4蛋白在膀胱癌组织内的表达较癌旁组织表达低,且其表达量与膀胱癌组织学分级相关。 Objective To investigate the expression of mammalian tissue inhibitor of metalloproteinase-4 (TIMP-4) in bladder urothelial cell carcinoma and normal tissue adjacent to carcinoma and its clinical significance. Methods Surgi- cal specimens of cancer tissues and normal tissue adjacent to carcinoma of 152 cases diagnosed as bladder urothelial cell carcinoma were collected from June 2015 to September 2016 in Department of Urology of Xijing Hospital. The im- munohistochemical staining was performed and the semi-quantitative scoring system was used to evaluate the extent and intensity of the staining. The expression of mammalian TIMP-4 in bladder urothelial cell carcinoma and normal tissue adjacent to carcinoma were analyzed by using semi-quantitative method. Results Immunobistocbemistry showed that TIMP-4 protein positive was staining in the cytoplasm of normal tissues and bladder carcinoma. The positive ex- pression rate of TIMP-4 in bladder urothelial cell carcinoma and normal tissue adjacent to carcinoma was 26.97% and 84.21% respectively, with statistical difference (P 〈 0.05). The positive expression rate of TIMP-4 in low-grade bladder papillary urothelial carcinoma and high-grade bladder papillary urothelial carcinoma was 38.71% and 18.89% respec- tively, with statistical difference (P 〈 0.05). Conclusion TIMP-4 expression level in bladder urotbelial cell carcinoma tissue is lower than that in normal tissue adjacent to carcinoma. The expression degree in bladder urothelial cell carcinoma is associated with histopathologic grade.
出处 《中国医药导报》 CAS 2017年第12期77-80,共4页 China Medical Herald
基金 国家自然科学基金资助项目(81272812)
关键词 基质金属蛋白酶抑制剂一4 膀胱尿路上皮癌 免疫组织化学染色 Mammalian tissue inhibitor of metalloproteinase-4 Bladder urothelial cell carcinoma Immunohistochemistry
  • 相关文献

参考文献1

二级参考文献30

  • 1Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18:1135-1149.
  • 2Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516.
  • 3Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:163-176.
  • 4Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999; 19:1589-1592.
  • 5Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103:1237-1241.
  • 6Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
  • 7Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity.Cancer Res 2000; 60:4745-4751.
  • 8Park HI, Ni J, Gerkema FE, et al. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000; 275:20540-20544.
  • 9de Coignac AB, Elson G, Delneste Y, et al. Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J Biochem 2000;267:3323-3329.
  • 10Marchenko GN, Ratnikov BI, Rozanov DV, et al. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2001 : 356:705-718

共引文献17

同被引文献37

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部